Evommune, Inc. EVMN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T01:28:25.970Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T00:00:00.002600567Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-13T01:28:25.607278+00:00
Evommune, Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 7.50 | 616.9% | 37.0% | |||
| 35Δ | 7.83 | 566.6% | 32.9% | |||
| 40Δ | 14.75 | 626.6% | 103.1% | 8.16 | 516.4% | 28.8% |
| 45Δ | 14.08 | 670.2% | 98.2% | 8.49 | 466.1% | 24.7% |
| 50Δ | 13.42 | 713.7% | 93.2% | 8.81 | 415.9% | 20.6% |
| 55Δ | 12.75 | 757.2% | 88.3% | 9.14 | 365.6% | 16.6% |
| 60Δ | 9.47 | 315.4% | 12.5% | |||
| 65Δ | 9.80 | 265.1% | 8.4% | |||
| 70Δ | 7.35 | 126.0% | 3.7% | |||
| 75Δ | 6.75 | 174.0% | 3.5% | |||
| 80Δ | 6.15 | 222.0% | 3.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.50
- IV
- 616.9%
- B/E move
- 37.0%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.83
- IV
- 566.6%
- B/E move
- 32.9%
40Δ
- Pseudo strike
- 14.75
- IV
- 626.6%
- B/E move
- 103.1%
- Pseudo strike
- 8.16
- IV
- 516.4%
- B/E move
- 28.8%
45Δ
- Pseudo strike
- 14.08
- IV
- 670.2%
- B/E move
- 98.2%
- Pseudo strike
- 8.49
- IV
- 466.1%
- B/E move
- 24.7%
50Δ
- Pseudo strike
- 13.42
- IV
- 713.7%
- B/E move
- 93.2%
- Pseudo strike
- 8.81
- IV
- 415.9%
- B/E move
- 20.6%
55Δ
- Pseudo strike
- 12.75
- IV
- 757.2%
- B/E move
- 88.3%
- Pseudo strike
- 9.14
- IV
- 365.6%
- B/E move
- 16.6%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.47
- IV
- 315.4%
- B/E move
- 12.5%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.80
- IV
- 265.1%
- B/E move
- 8.4%
70Δ
- Pseudo strike
- 7.35
- IV
- 126.0%
- B/E move
- 3.7%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 6.75
- IV
- 174.0%
- B/E move
- 3.5%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 6.15
- IV
- 222.0%
- B/E move
- 3.3%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 178.51% | |
| 196.10% | |
| 256.64% | |
| 127.86% | |
| 135.06% | |
| 131.23% | |
| 141.53% | |
| 141.72% | |
| 137.48% | |
| 158.88% | |
| 169.91% | |
| 175.92% | |
| 178.19% | |
| 176.81% | |
| 215.45% | |
| 225.54% | |
| 258.48% | |
| 174.95% | |
| 164.98% | |
| 169.37% | |
| 201.90% | |
| 286.75% | |
| 247.14% |
Biotechnology
EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
More →EXEL
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The…
More →EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United…
More →FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is…
More →FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in…
More →FENC
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in…
More →